CPRX Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list.

“We are honored to once again be recognized on Forbes’ list of America’s Most Successful Small-Cap Companies for 2026,” said Rich Daly, President and CEO, Catalyst. “Our accomplishments over the past year reflect the unwavering dedication of all our employees and our unwavering commitment to the rare disease patient communities we serve.”

To compile the list, Forbes used data from FactSet to find 621 companies with a market value between $300 million and $5 billion that also had positive sales growth over the past 12 months and a share price of at least $5. Financial institutions, REITs, utilities, royalty trusts and limited partnerships were excluded, as were companies that have been public for less than one year. The top 100 stocks were ranked based on earnings growth, sales growth, return on equity and total stock return for the last five years available, with more weight given to the last 12 months of data. All data is as of October 31, 2025.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst's website at .



Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
 

Media Contact
David Schull
(858) 717-2310
 
EN
08/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Catalyst Pharmaceuticals

 PRESS RELEASE

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 L...

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out ...

 PRESS RELEASE

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugur...

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the...

Catalyst Pharmaceuticals Inc: 1 director

A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch